Track Citius Oncology's total revenue ($5.6M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
Citius Oncology (CTOR) currently reports a total revenue of $5.6M as of March 2026. In the prior-year period, the figure was $0. That is below the sector sector average of $1.3B. Use the charts on this page to explore Citius Oncology's total revenue history and peer comparisons.
Citius Oncology's total revenue changed from $0 to $5.6M (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Citius Oncology's total revenue of $5.6M is lower than the its sector sector average of $1.3B. That is roughly 99.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Citius Oncology reported $5.6M in total revenue as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total revenue of $5.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $1.3B. From there, open related valuation or income-statement pages for Citius Oncology, and consider following CTOR for alerts when major investors trade the stock.